Adult
SandostatinR Inj.--
Acromegaly: SC, initial 50 μg 3 times/d; maintenance, 100-500μg 3 times/d.
Gastrointestinal tumors:SC, 50μg 2-3 times/d. The dose being increased gradually according to patient tolerance and response.
Carcinoid tumor: SC, initial 100-600 μg/d in 2-4 divided doses for 2 wks; maintenance, 50-1500 μg/d.
Vasoactive intestinal polypeptide–secreting tumors (VIPomas): SC, initial 200-300 μg in 2-4 divided doses for 2 wks; maintenance, adjust to achieve therapeutic response
Max. Acromegaly: 1500 μg/d
Sandostatin LARR Inj.--
Acromegaly: IM, initial 20 mg intragluteally at 4-wk intervals for 3 months
After initial 3 months, continue 20 mg intragluteally every 4 wks if GH is< 2.5 ng/ml, IGF-I is normal, and clinical symptoms have improved
After initial 3 months, increase to 30 mg intragluteally every 4 wks if GH is> 2.5 ng/ml, IGF-I is elevated, and/or clinical symptoms uncontrolled
After initial 3 months, decrease to 10 mg IM intragluteally every 4 wks if GH is< 1 ng/ml, IGF-I is normal, and clinical symptoms are controlled
Increase dose to 40 mg IM intragluteally every 4 wks in patients whose GH, IGF-1, and symptoms are not adequately controlled at 30 mg
Carcinoid tumor: IM, initial 20 mg intragluteally at 4-wk intervals for 2 months (octreotide acetate injectable suspension); continue SC octreotide acetate injections for at least 2 wks during the switch to octreotide acetate injectable suspension.
After 2 months of initial therapy, increase dose to 30 mg intragluteally every 4 wks if symptoms not adequately controlled
After 2 mo of initial therapy, decrease dose to 10 mg intragluteally in patients who achieve good symptom control; increase dose to 20 mg IM every 4 wks if symptoms recur
Max. Gastrointestinal tumors: 30 mg every 4 wks; Acromegaly: 40 mg every 4 wks.
Pediatric
SandostatinR Inj.
Gastrointestinal tumors: SC, 1-10 μg/kg/d. |
